Oridion
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$15.0m | Series A | ||
N/A | - | ||
N/A | Acquisition | ||
Total Funding | €13.6m |
Related Content
Recent News about Oridion
EditOridion specializes in capnography, a technology used to monitor the concentration of carbon dioxide in respiratory gases, primarily serving healthcare providers and medical institutions. Operating in the medical technology market, Oridion's core product is its Microstream® capnography technology, which provides accurate and continuous monitoring of patients' respiratory status. The business model revolves around the sale of capnography devices, disposable accessories, and related software solutions. Revenue is generated through direct sales to hospitals, clinics, and other healthcare facilities, as well as through partnerships with medical device manufacturers. Oridion's technology is particularly valuable in critical care, emergency medicine, and anesthesia, where precise respiratory monitoring is crucial. The company aims to improve patient safety and clinical outcomes by providing reliable and easy-to-use capnography solutions.
Keywords: capnography, respiratory monitoring, Microstream®, healthcare, patient safety, clinical outcomes, medical technology, critical care, emergency medicine, anesthesia.